A recent study showed that primary T cells transduced with a multi-specific CAR (targeting both the gp120 CD4-binding site and the gp120 co-receptor–binding site) had the ability to potently reduce cellular HIV infection by up to 99% in vitro and >97% in vivo (108). Here, CD4 is linked to HIV infectious disease.